Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Genmab A/S

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

COMPANY ANNOUNCEMENT COPENHAGEN, DENMARK; MAY 12, 2026  GENMAB A/S (NASDAQ: GMAB) WILL INCREASE ITS SHARE CAPITAL BY 2,346 SHARES AS A CONSEQUENCE OF THE EXERCISE OF EMPLOYEE WARRANTS. THE INCREASE IS EFFECTED WITHOUT ANY PREEMPTION RIGHTS FOR THE EXISTING SHAREHOLDERS OF THE COMPANY OR OTHERS.

CAPITAL INCREASE IN GENMAB AS A RESULT OF EMPLOYEE WARRANT EXERCISE

MAY 7, 2026 COPENHAGEN, DENMARK; INTERIM REPORT FOR THE THREE MONTHS ENDED MARCH 31, 2026 HIGHLIGHTS GENMAB REVENUE INCREASED 25% COMPARED TO THE FIRST THREE MONTHS OF 2025 , TO $896 MILLION FDA APPROVED AN SBLA TO REMOVE THE RECOMMENDATION FOR 24-HOUR HOSPITALIZATION FOR PATIENTS WITH THIRD LINE PLUS RELAPSED/REFRACTORY DLBCL REMAINED FOCUSED ON DISCIPLINED INVESTMENT IN OUR LATE-STAGE PORTFOLIO, EPKINLY  (EPCORITAMAB), RINA-S  , AND PETOSEMTAMAB, INCLUDING LAUNCH READINESS WE MADE TANGIBLE PROGRESS IN THE FIRST QUARTER AS WE CONTINUE TO INTEGRATE MERUS AND ADVANCE OUR LATE-STAGE PORTFOLIO - EPKINLY, RINA-S AND PETOSEMTAMAB. ACROSS THE BUSINESS, OUR FOCUS REMAINED ON DISCIPLINED EXECUTION, PROGRESSING THESE PROGRAMS TOWARD KEY READOUTS AND PREPARING FOR POTENTIAL LAUNCHES TO HAVE AN IMPACT ON MORE PATIENTS, SAID JAN VAN DE WINKEL, PH.D.

GENMAB ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2026

COMPANY ANNOUNCEMENT COPENHAGEN, DENMARK; APRIL 17, 2026  GENMAB A/S (NASDAQ: GMAB) AT GENMAB A/S' ANNUAL GENERAL MEETING ON MARCH 19, 2026, IT WAS DECIDED TO REDUCE THE COMPANY'S SHARE CAPITAL WITH NOMINALLY DKK 1,900,000 BY CANCELLATION OF 1,900,000 OF THE COMPANY'S HOLDING OF SHARES WITH A NOMINAL VALUE OF DKK 1 EACH. THE SHARE CAPITAL REDUCTION HAS TODAY BEEN REGISTERED WITH THE DANISH BUSINESS AUTHORITY.

GENMAB A/S SHARE CAPITAL REDUCTION

COMPANY ANNOUNCEMENT MAJOR SHAREHOLDER ANNOUNCEMENT FOR GENMAB A/S COPENHAGEN, DENMARK; APRIL 14, 2026  GENMAB A/S (NASDAQ: GMAB) ANNOUNCES UNDER REFERENCE TO SECTION 30 OF THE DANISH CAPITAL MARKETS ACT THAT ORBIS INVESTMENT MANAGEMENT LIMITED HAS INFORMED US THAT, AS OF APRIL 13, 2026, ORBIS INVESTMENT MANAGEMENT LIMITED THROUGH SHARES CONTROLLED THE VOTING RIGHTS TO 3,114,318 SHARES IN GENMAB A/S, WHICH AMOUNTS TO 4.85% OF THE SHARE CAPITAL AND VOTING RIGHTS IN GENMAB A/S.  THE MAJOR SHAREHOLDER ANNOUNCEMENT OF ORBIS INVESTMENT MANAGEMENT LIMITED IS ATTACHED TO THIS ANNOUNCEMENT.

MAJOR SHAREHOLDER ANNOUNCEMENT

COMPANY ANNOUNCEMENT NET SALES OF DARZALEX  IN THE FIRST QUARTER OF 2026 TOTALED USD 3,964 MILLION GENMAB RECEIVES ROYALTIES ON WORLDWIDE NET SALES FROM JOHNSON & JOHNSON (J&J, LEGAL ENTITY JANSSEN BIOTECH, INC.) COPENHAGEN, DENMARK; APRIL 14, 2026  GENMAB A/S (NASDAQ: GMAB) ANNOUNCED TODAY THAT WORLDWIDE NET TRADE SALES OF DARZALEX (DARATUMUMAB), INCLUDING SALES OF THE SUBCUTANEOUS (SC) PRODUCT ( DARATUMUMAB AND HYALURONIDASE-FIHJ , SOLD UNDER THE TRADENAME DARZALEX FASPRO  IN THE U.S. ) , AS REPORTED BY J&J WERE USD 3,964 MILLION IN THE FIRST QUARTER OF 2026. NET TRADE SALES WERE USD 2,208 MILLION IN THE U.S. AND USD 1,756 MILLION IN THE REST OF THE WORLD.

GENMAB ANNOUNCES NET SALES OF DARZALEX (DARATUMUMAB) FOR FIRST QUARTER OF 2026

COPENHAGEN, DENMARK--(BUSINESS WIRE)--GENMAB A/S (NASDAQ: GMAB) ANNOUNCED TODAY NEW DATA DEMONSTRATING THAT RINATABART SESUTECAN (RINA-S), AN INVESTIGATIONAL FOLATE RECEPTOR ALPHA (FR)-TARGETED, TOPOISOMERASE I (TOPO1)-INHIBITOR ANTIBODY-DRUG CONJUGATE (ADC), EVALUATED IN COMBINATION WITH BEVACIZUMAB IN PATIENTS WITH ADVANCED OVARIAN CANCER, SHOWED A SAFETY PROFILE CONSISTENT WITH THE KNOWN SAFETY PROFILES OF RINA-S AND BEVACIZUMAB. THESE DATA ARE FROM THE COMBINATION THERAPY COHORT D2 OF THE.

GENMAB PRESENTS THE SAFETY AND TOLERABILITY OF RINATABART SESUTECAN (RINA-S) IN COMBINATION WITH BEVACIZUMAB IN ADVANCED OVARIAN CANCER

COMPANY ANNOUNCEMENT COPENHAGEN, DENMARK; APRIL 1, 2026  GENMAB A/S (NASDAQ: GMAB) - THIS DOCUMENT DISCLOSES THE DATA OF THE TRANSACTIONS MADE IN GENMAB A/S (NASDAQ: GMAB) BY MANAGERIAL EMPLOYEES AND THEIR CLOSELY ASSOCIATED PERSONS. IN ACCORDANCE WITH ARTICLE 19 OF REGULATION NO.

TRANSACTIONS WITH SHARES AND LINKED SECURITIES IN GENMAB A/S MADE BY MANAGERIAL EMPLOYEES AND THEIR CLOSELY ASSOCIATED PERSONS

COMPANY ANNOUNCEMENT MAJOR SHAREHOLDER ANNOUNCEMENT FOR GENMAB A/S COPENHAGEN, DENMARK; APRIL 1, 2026  GENMAB A/S (NASDAQ: GMAB) ANNOUNCES UNDER REFERENCE TO SECTION 30 OF THE DANISH CAPITAL MARKETS ACT THAT ORBIS INVESTMENT MANAGEMENT LIMITED HAS INFORMED US THAT, AS OF MARCH 31, 2026, ORBIS INVESTMENT MANAGEMENT LIMITED THROUGH SHARES CONTROLLED THE VOTING RIGHTS TO 3,221,620 SHARES IN GENMAB A/S, WHICH AMOUNTS TO 5.01% OF THE SHARE CAPITAL AND VOTING RIGHTS IN GENMAB A/S.  THE MAJOR SHAREHOLDER ANNOUNCEMENT OF ORBIS INVESTMENT MANAGEMENT LIMITED IS ATTACHED TO THIS ANNOUNCEMENT.

COMPANY ANNOUNCEMENT MAJOR SHAREHOLDER ANNOUNCEMENT FOR GENMAB A/S COPENHAGEN, DENMARK; MARCH 30, 2026  GENMAB A/S (NASDAQ: GMAB) ANNOUNCES UNDER REFERENCE TO SECTION 30 OF THE DANISH CAPITAL MARKETS ACT THAT ORBIS INVESTMENT MANAGEMENT LIMITED HAS INFORMED US THAT, AS OF MARCH 27, 2026, ORBIS INVESTMENT MANAGEMENT LIMITED THROUGH SHARES CONTROLLED THE VOTING RIGHTS TO 3,205,763 SHARES IN GENMAB A/S, WHICH AMOUNTS TO 4.99% OF THE SHARE CAPITAL AND VOTING RIGHTS IN GENMAB A/S.  THE MAJOR SHAREHOLDER ANNOUNCEMENT OF ORBIS INVESTMENT MANAGEMENT LIMITED IS ATTACHED TO THIS ANNOUNCEMENT.

COMPANY ANNOUNCEMENT COPENHAGEN, DENMARK; MARCH 19, 2026  GENMAB A/S (NASDAQ: GMAB) FOLLOWING GENMAB A/S' ANNUAL GENERAL MEETING HELD ON MARCH 19, 2026, THE COMPANY'S BOARD OF DIRECTORS MET TO CONSTITUTE ITSELF.MS. DEIRDRE P. CONNELLYWAS APPOINTED CHAIR ANDMS. PERNILLE ERENBJERGWAS APPOINTED DEPUTY CHAIR.IT WAS DECIDED TOGRANT 5,213RESTRICTED STOCK UNITSAND 4,485 WARRANTS TO THE EMPLOYEES OF THE COMPANY AND THE COMPANY'S SUBSIDIARIES. EACH RESTRICTED STOCK UNIT IS AWARDED COST-FREE AND PROVIDES THE OWNER WITH A CONDITIONAL RIGHT TO RECEIVE ONE SHARE IN GENMAB A/S OF NOMINALLY DKK 1. THE FAIR VALUE OF EACH RESTRICTED STOCK UNIT IS EQUAL TO THE CLOSING MARKET PRICE ON THE DATE OF GRANT OF ONE GENMAB A/S SHARE, DKK 1,645.00. THE RESTRICTED STOCK UNITS WILL VEST ON THE FIRST BANKING DAY OF THE MONTH FOLLOWING A PERIOD OF THREE YEARS FROM THE DATE OF GRANT. FURTHERMORE, THE RESTRICTED STOCK UNITS ARE SUBJECT TO VESTING CONDITIONS SET OUT IN THE RESTRICTED STOCK UNIT PROGRAM ADOPTED BY THE BOARD OF DIRECTORS. INFORMATION CONCERNING GENMAB'S RESTRICTED STOCK UNIT PROGRAM CAN BE FOUND ONWWW.GENMAB.COMUNDER INVESTORS > GOVERNANCE > COMPENSATION > RESTRICTED STOCK UNITS. THE EXERCISE PRICE FOR EACH WARRANT IS DKK 1,645.00. EACH WARRANT IS AWARDED COST-FREE AND ENTITLES THE OWNER TO SUBSCRIBE ONE SHARE OF NOMINALLY DKK 1 SUBJECT TO PAYMENT OF THE EXERCISE PRICE. BY APPLICATION OF THE BLACK-SCHOLES FORMULA, THE FAIR VALUE OF EACH WARRANT CAN BE CALCULATED AS DKK 530.62. THE WARRANTS VEST THREE YEARS AFTER THE GRANT DATE, AND ALL WARRANTS EXPIRE AT THE SEVENTH ANNIVERSARY OF THE GRANT DATE. THE NEW WARRANTS HAVE BEEN GRANTED ON THE TERMS AND CONDITIONS SET OUT IN THE WARRANT PROGRAM ADOPTED BY THE BOARD OF DIRECTORS ON FEBRUARY 23, 2021. INFORMATION CONCERNING GENMAB'S WARRANT SCHEMES CAN BE FOUND ONWWW.GENMAB.COMUNDER INVESTORS > GOVERNANCE > COMPENSATION > WARRANTS.

CONSTITUTION OF THE BOARD OF DIRECTORS IN GENMAB A/S AND GRANT OF RESTRICTED STOCK UNITS AND WARRANTS TO EMPLOYEES IN GENMAB

COMPANY ANNOUNCEMENT AT GENMAB A/S' ANNUAL GENERAL MEETING HELD TODAYMARCH 19, 2026,THE ANNUAL REPORT FOR 2025WASAPPROVED DISCHARGE WAS GIVEN TO THE BOARD OF DIRECTORS AND THE EXECUTIVE MANAGEMENT AND THE YEAR'S PROFIT WAS CARRIEDFORWARD THE 2025COMPENSATION REPORT WASAPPROVED SIXMEMBERS OF THE BOARD OF DIRECTORS WERERE-ELECTED DELOITTE WAS RE-ELECTED AS THE AUDITOR OF THECOMPANY THE PROPOSALFROM THE BOARD OF DIRECTORSTO REDUCE THE COMPANY'S SHARE CAPITAL WITH NOMINALLY DKK 1,900,000 BY CANCELLATION OF THE COMPANY'S HOLDING OF SHARES WASADOPTED COPENHAGEN, DENMARK;MARCH 19,2026 GENMAB A/S (NASDAQ:GMAB)HELD ITS ANNUAL GENERAL MEETING, TODAY AT THE COPENHAGEN MARRIOTT HOTEL, COPENHAGEN, DENMARK.AT THE MEETING, DEIRDRE P.

PASSING OF GENMAB A/S' ANNUAL GENERAL MEETING

COMPANY ANNOUNCEMENT COPENHAGEN, DENMARK; MARCH 16, 2026  GENMAB A/S (NASDAQ: GMAB) ANNOUNCES THAT ITSSHARE BUY-BACK PROGRAM HAS BEEN COMPLETED ON MARCH 13, 2026. ON FEBRUARY 17, 2026, GENMAB ANNOUNCED THE INITIATION OF A SHARE BUY-BACK PROGRAM TO REPURCHASE UP TO 342,130 SHARES WITH A MAXIMUM AGGREGATE TOTAL VALUE OF 725 MILLION DKK TO HONOR OUR COMMITMENTS UNDER THE RESTRICTED STOCK UNIT PROGRAM.

Genmab A/S

GMAB

Price

Financial Reports

No items found.

Press Releases

Genmab A/S

GMAB.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

GMAB